1,601 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Meriwether Wealth & Planning LLC

Meriwether Wealth & Planning LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,601 shares of the medical research company’s stock, valued at approximately $417,000.

A number of other institutional investors also recently bought and sold shares of AMGN. Tower Wealth Partners Inc. increased its holdings in shares of Amgen by 4.7% during the 4th quarter. Tower Wealth Partners Inc. now owns 1,416 shares of the medical research company’s stock valued at $369,000 after purchasing an additional 63 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Amgen by 14.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 208,167 shares of the medical research company’s stock worth $54,257,000 after purchasing an additional 25,692 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in Amgen by 4.1% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 29,523 shares of the medical research company’s stock worth $7,695,000 after purchasing an additional 1,159 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Amgen by 3.9% during the 4th quarter. AlphaQuest LLC now owns 1,993 shares of the medical research company’s stock valued at $519,000 after acquiring an additional 74 shares during the last quarter. Finally, Ellerson Group Inc. ADV boosted its position in shares of Amgen by 11.3% during the 4th quarter. Ellerson Group Inc. ADV now owns 12,159 shares of the medical research company’s stock valued at $3,169,000 after acquiring an additional 1,230 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by insiders.

Amgen Stock Up 2.2 %

AMGN opened at $324.86 on Monday. The company has a fifty day moving average price of $286.14 and a 200-day moving average price of $299.48. The firm has a market capitalization of $174.52 billion, a P/E ratio of 43.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Wall Street Analyst Weigh In

A number of research firms have commented on AMGN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Truist Financial cut their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Citigroup restated a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Redburn Partners lowered their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $314.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.